Amna Mohamed
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Amna Mohamed has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
Anas Hamad
National Center for Cancer Care & Research, Hamad Medical Corporation
1 shared publication- Asim Jamal Shaikh
Sultan Qaboos Comprehensive Cancer Care and Research Centre (SQCCCRC) Muscat, Oman
1 shared publication Bushra Salman
Sultan Qaboos Comprehensive Cancer Care and Research Center
1 shared publication- Bushra Salman
Pharmacy Department, National Hematology and Bone Marrow Transplant Center, University Medical City, Oman
1 shared publication - Bushra Salman
Department of Pharmacology and Clinical Pharmacy, Sultan Qaboos University, Al Khoudh, Muscat P.O. Box 50, Oman
1 shared publication Intisar Al-Riyami
Sultan Qaboos University Hospital, University Medical City
1 shared publication
Latest Publications
- Open Access
- 8 November 2026
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (11) , 1772
Hydroxyurea Pharmacokinetics and Precision Dosing in Sickle Cell Disease: A Scoping Review
Background: Hydroxyurea is the cornerstone disease-modifying therapy for sickle cell disease (SCD), but interindividual pharmacokinetic (PK) variability contributes to differences in drug exposure and treatment response. This scoping review synthesised evidence on hydroxyurea PK, pharmacodynamic (PD) relationships, determinants of exposure, pharmacometric modelling, and precision dosing approaches in SCD. Methods: A scoping review was conducted according to PRISMA-ScR guidance. Studies involving paediatric or adult patients with SCD that evaluated hydroxyurea PK, PK-PD relationships, exposure determinants, pharmacometric modelling, or PK-guided dosing were included. Study characteristics, PK parameters, covariates, modelling approaches, and key findings were charted and synthesised descriptively. Results: Twenty-seven studies published between 2005 and 2026 were included. Hydroxyurea demonstrated rapid oral absorption (Tmax 0.73–1.7 h), a short elimination half-life (1.7–2.9 h), and variability in systemic exposure across individuals (coefficient of variation approximately 40–45%). Body weight and renal function were the most consistently identified determinants of disposition, with renal impairment associated with reduced clearance and increased exposure. PK of hydroxyurea were well described by population PK and physiologically based PK models. PK-guided dosing showed potential to shorten the time to maximum tolerated dose and improve haematological responses. However, exposure–response and exposure–toxicity relationships remain insufficiently characterised, and evidence directly linking hydroxyurea exposure to patient-centred clinical outcomes was limited. Conclusions: Pharmacometric modelling and model-informed precision dosing (MIPD) have potential to support individualised hydroxyurea therapy, particularly in paediatric patients and those with altered renal function. Prospective external validation across diverse paediatric and adult populations, together with validated exposure–response and exposure–toxicity targets and clinically meaningful efficacy and safety outcomes, is required before routine clinical application can be recommended.
- 8 November 2026
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (11) , 1772
Open AccessHydroxyurea Pharmacokinetics and Precision Dosing in Sickle Cell Disease: A Scoping Review
Background: Hydroxyurea is the cornerstone disease-modifying therapy for sickle cell disease (SCD), but interindividual pharmacokinetic (PK) variability contributes to differences in drug exposure and treatment response. This scoping review synthesised evidence on hydroxyurea PK, pharmacodynamic (PD) relationships, determinants of exposure, pharmacometric modelling, and precision dosing approaches in SCD. Methods: A scoping review was conducted according to PRISMA-ScR guidance. Studies involving paediatric or adult patients with SCD that evaluated hydroxyurea PK, PK-PD relationships, exposure determinants, pharmacometric modelling, or PK-guided dosing were included. Study characteristics, PK parameters, covariates, modelling approaches, and key findings were charted and synthesised descriptively. Results: Twenty-seven studies published between 2005 and 2026 were included. Hydroxyurea demonstrated rapid oral absorption (Tmax 0.73–1.7 h), a short elimination half-life (1.7–2.9 h), and variability in systemic exposure across individuals (coefficient of variation approximately 40–45%). Body weight and renal function were the most consistently identified determinants of disposition, with renal impairment associated with reduced clearance and increased exposure. PK of hydroxyurea were well described by population PK and physiologically based PK models. PK-guided dosing showed potential to shorten the time to maximum tolerated dose and improve haematological responses. However, exposure–response and exposure–toxicity relationships remain insufficiently characterised, and evidence directly linking hydroxyurea exposure to patient-centred clinical outcomes was limited. Conclusions: Pharmacometric modelling and model-informed precision dosing (MIPD) have potential to support individualised hydroxyurea therapy, particularly in paediatric patients and those with altered renal function. Prospective external validation across diverse paediatric and adult populations, together with validated exposure–response and exposure–toxicity targets and clinically meaningful efficacy and safety outcomes, is required before routine clinical application can be recommended.
- 29 August 2025
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
- Vol. 32 (4) , 691-708
Oncology stewardship: A narrative review of principles and practices
Introduction: The rising costs, complexity, and ethical challenges of anticancer therapies have created an urgent need for structured frameworks to ensure clinical efficacy, cost-effectiveness, and equitable access. Oncology stewardship (OS) has emerged as a promising model to optimize oncology pharmacotherapy and resource allocation. However, the lack of a unified model for OS implementation and evaluation represents a critical gap. This review addresses this by synthesizing emerging practices and policy considerations to inform the structured integration of OS into oncology systems. Methods: This narrative review followed the conceptual synthesis approach outlined by Baumeister & Leary (1997) and Green et al. (2006), to develop a coherent understanding of OS as a clinical and policy framework. English-language sources published between 2001 and 2025 were purposively selected from PubMed, Scopus, and Google Scholar. Thematic analysis was used to organize and interpret findings. Results: Five core domains were identified: (1) systemic drivers necessitating OS, including rising costs, drug shortages, safety concerns, and ethical considerations; (2) core operational strategies such as pre-authorization, dose optimization, site-of-care transitions, biosimilar adoption, and biomarker-guided therapy; (3) the governance role of Pharmacy and Therapeutics Committees in formulary management and clinical decision-making; (4) structural components and outcome metrics to assess the clinical, economic, and operational impact of OS; and (5) implementation barriers such as stakeholder resistance, limited infrastructure, and regulatory gaps. The review also highlights that although many OS initiatives demonstrate clinical and financial promise, their success is often limited by voluntary, fragmented implementation and a lack of standardized evaluation. Conclusion: OS offers a critical but underutilized framework for improving the quality, safety, and sustainability of oncology care. While several operational models and interventions have shown promise, their fragmented adoption and weak regulatory support hinder scalability. Advancing OS will require national-level policy integration, investment in implementation infrastructure, and the development of standardized metrics to guide evaluation and accountability.
- 29 August 2025
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
- Vol. 32 (4) , 691-708
Oncology stewardship: A narrative review of principles and practices
Introduction: The rising costs, complexity, and ethical challenges of anticancer therapies have created an urgent need for structured frameworks to ensure clinical efficacy, cost-effectiveness, and equitable access. Oncology stewardship (OS) has emerged as a promising model to optimize oncology pharmacotherapy and resource allocation. However, the lack of a unified model for OS implementation and evaluation represents a critical gap. This review addresses this by synthesizing emerging practices and policy considerations to inform the structured integration of OS into oncology systems. Methods: This narrative review followed the conceptual synthesis approach outlined by Baumeister & Leary (1997) and Green et al. (2006), to develop a coherent understanding of OS as a clinical and policy framework. English-language sources published between 2001 and 2025 were purposively selected from PubMed, Scopus, and Google Scholar. Thematic analysis was used to organize and interpret findings. Results: Five core domains were identified: (1) systemic drivers necessitating OS, including rising costs, drug shortages, safety concerns, and ethical considerations; (2) core operational strategies such as pre-authorization, dose optimization, site-of-care transitions, biosimilar adoption, and biomarker-guided therapy; (3) the governance role of Pharmacy and Therapeutics Committees in formulary management and clinical decision-making; (4) structural components and outcome metrics to assess the clinical, economic, and operational impact of OS; and (5) implementation barriers such as stakeholder resistance, limited infrastructure, and regulatory gaps. The review also highlights that although many OS initiatives demonstrate clinical and financial promise, their success is often limited by voluntary, fragmented implementation and a lack of standardized evaluation. Conclusion: OS offers a critical but underutilized framework for improving the quality, safety, and sustainability of oncology care. While several operational models and interventions have shown promise, their fragmented adoption and weak regulatory support hinder scalability. Advancing OS will require national-level policy integration, investment in implementation infrastructure, and the development of standardized metrics to guide evaluation and accountability.
- 6 May 2024
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
- Vol. 31 (4) , 616-626
Evaluating the clinical benefit of pembrolizumab as a first-line agent in advanced solid tumors: A comprehensive review
Introduction: The study evaluates the first-line application of pembrolizumab in metastatic non-small-cell lung cancer (mNSCLC), head and neck squamous cell cancer (HNSCC), gastric cancer, and renal cell carcinoma. Utilizing the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) and the American Society of Clinical Oncology Value Framework (ASCO-VF), the analysis incorporates data from pivotal KEYNOTE trials. Methods: The study systematically assessed the clinical benefit of pembrolizumab in advanced solid malignancies through nine randomized controlled trials, one of which comprised two experimental arms. Data extraction from primary sources was conducted from PubMed, ASCO, and ESMO publications. Utilizing ESMO-MCBS and ASCO-VF forms, the evaluation focused on clinical benefit, toxicity, and bonus points, with discrepancies resolved through consensus discussions. Results: Nine first-line indications for pembrolizumab received Food and Drug Administration approval for metastatic solid tumors between 2018 and 2023. Notable distinctions in ESMO-MCBS grades revealed seven trials with substantial clinical benefit (grades 5 to 4) and three with moderate to negligible benefit (grades 3 to 1). Bonus points, primarily based on the tail of the curve, were allocated to three trials for overall survival, one for progression-free survival, and one for a significant improvement in quality of life. Conclusions: Our evaluation of pembrolizumab across diverse cancers, especially in mNSCLC and HNSCC, revealed varied outcomes and challenges in clinical benefit interpretation. The assessment of clinical benefit, incorporating quantitative and qualitative endpoints, underscores the need to consider survivorship outcomes and patient perspectives for a comprehensive understanding.
- 6 May 2024
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
- Vol. 31 (4) , 616-626
Evaluating the clinical benefit of pembrolizumab as a first-line agent in advanced solid tumors: A comprehensive review
Introduction: The study evaluates the first-line application of pembrolizumab in metastatic non-small-cell lung cancer (mNSCLC), head and neck squamous cell cancer (HNSCC), gastric cancer, and renal cell carcinoma. Utilizing the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) and the American Society of Clinical Oncology Value Framework (ASCO-VF), the analysis incorporates data from pivotal KEYNOTE trials. Methods: The study systematically assessed the clinical benefit of pembrolizumab in advanced solid malignancies through nine randomized controlled trials, one of which comprised two experimental arms. Data extraction from primary sources was conducted from PubMed, ASCO, and ESMO publications. Utilizing ESMO-MCBS and ASCO-VF forms, the evaluation focused on clinical benefit, toxicity, and bonus points, with discrepancies resolved through consensus discussions. Results: Nine first-line indications for pembrolizumab received Food and Drug Administration approval for metastatic solid tumors between 2018 and 2023. Notable distinctions in ESMO-MCBS grades revealed seven trials with substantial clinical benefit (grades 5 to 4) and three with moderate to negligible benefit (grades 3 to 1). Bonus points, primarily based on the tail of the curve, were allocated to three trials for overall survival, one for progression-free survival, and one for a significant improvement in quality of life. Conclusions: Our evaluation of pembrolizumab across diverse cancers, especially in mNSCLC and HNSCC, revealed varied outcomes and challenges in clinical benefit interpretation. The assessment of clinical benefit, incorporating quantitative and qualitative endpoints, underscores the need to consider survivorship outcomes and patient perspectives for a comprehensive understanding.